Ultragenyx Pharmaceutical | RARE - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Immunic USD 23.33M 2.67M 2025-12
Insmed USD 526.79M 20.55M 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Kyowa Hakko Kirin JPY 122.9B 13.95B 2026-06
MacroGenics USD 21.2M 32.13M 2026-03
Moderna USD 960M 817M 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06